Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Cisbio's line of HTRF KinEASE kits is based on our patented HTRF technology and can be used as a universal tool for assessing tyrosine kinase activity. HTRF KinEASE kits limit assay development ...

While it is understood that this fusion activates tyrosine kinase signaling, the mechanisms of transformation and importance of perturbation of EBF1 activity remain unknown. EBF1 is a nuclear ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Dr. Owen Witte(Link is external) (Link opens in new window) with the twelfth ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...

Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor ... the change from baseline to week 12 in the urticaria activity score during a 7-day period (UAS7), which comprises ...

Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the stock. Oncternal ...

This led to a decrease in PDHA1 S293 phosphorylation and an increase in PDH enzyme activity ... TIE1, a receptor tyrosine kinase, was found to be upregulated by ING5 and capable of directly ...